Key points are not available for this paper at this time.
The objective is to assess the performance of the 2023 American College of Rheumatology/EULAR classification criteria (2023 AECC) for antiphospholipid syndrome (APS) in a Mexican cohort.
Cimé‐Aké et al. (Fri,) studied this question.